In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


2013: The Year In Diagnostics

Executive Summary

Concerns over patents, the anticipated regulatory oversight over complex tests, and reimbursement and evidence development characterized the continued upheaval in the diagnostics industry over the past year. However, genomics tools and technologies continue to be refined and introduced commercially, and companies with a sharp marketplace focus are showing they can still rise to the top.


Related Content

FDA Comes Down Hard On 23andMe, Putting Consumer-Directed Genetic Testing On Notice
Noninvasive Prenatal Screening: Battleground In Diagnostics Innovation
Illumina’s Unique Leverage In NIPT
Myriad Gets Mixed Decision in Supreme Court; Biotech Industry Fears Fallout
Life Technologies Extends Thermo Fisher’s Reach Into Clinical Practice
Veracyte: How To Build A Molecular Cytology Company
Trends In Diagnostics – 2012
Supreme Court Overturns Personalized Medicine Patents, Creating Confusion In Diagnostics Realm
Roche Pounces On Market-Weakened Illumina
Trends In Diagnostics 2011


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts